Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Datopotamab deruxtecan (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms TROPION-LUNG01
- Sponsors Daiichi Sankyo Inc
- 03 Sep 2024 According to an AstraZeneca media release, clinical data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress, September 13 to 17, 2024.
- 03 Sep 2024 According to an AstraZeneca media release, a late-breaking oral presentation at WCLC will showcase OS data from the TROPION-Lung01 Phase III trial evaluating datopotamab deruxtecan in patients with previously treated locally advanced or metastatic NSCLC.
- 03 Sep 2024 According to an AstraZeneca media release, a late-breaking Presidential Symposium at WCLC of exploratory results from the application of companys proprietary computational pathology platform, quantitative continuous scoring (QCS), to tissue samples collected in TROPION-Lung01 will demonstrate the potential of TROP2, as measured by QCS, as a predictive biomarker for datopotamab deruxtecan.